Menu
Innovation Observatory > Drugs

Results

Drugs

December 2017

Dabigatran Etexilate (Pradaxa) for Secondary Stroke Prevention in Patients with Embolic Stroke of Undetermined Source – First Line

Dabigatran etexilate is an oral drug that acts by preventing clots from forming and blocking blood vessels. It is already available for the treatment and prevention of stroke and other types of blood clots affecting blood vessels and organs in the body. By preventing clots from forming, it can prevent future embolic strokes.

Drugs

December 2017

Nab-paclitaxel in Combination with Gemcitabine for Resected Pancreatic Ductal Adenocarcinoma – Adjuvant Therapy

Paclitaxel formulated as albumin bound nanoparticles (Nab-paclitaxel) in combination with gemcitabine is being developed as a treatment option for patients with pancreatic cancer who have undergone surgery to increase the chances of being cured (‘adjuvant therapy’). Both drugs are chemotherapies already being used to treat metastatic pancreatic cancer and other types of cancers and are administered by injection.

Drugs

December 2017

Cannabidiol (Epidiolex®) for Tuberous Sclerosis Complex – add-on therapy

Cannabidiol is a medicine that is being developed for the treatment of TSC patients who experience inadequately-controlled seizures. It is being developed as an oral medicine to be added to existing treatment options for TSC (‘add-on therapy’).

Drugs

December 2017

Blinatumomab (Blincyto) for First Relapsed/Refractory, B-precursor, Acute Lymphoblastic Leukaemia, in Children and Adolescents

Blinatumomab is a type of drug called a monoclonal antibody. Monoclonal antibodies work by seeking out cancer cells by looking for particular proteins on the cells’ surface. Blinatumomab is a new drug that is already used to treat ALL in adults and is currently being studied to see how well it works and whether it is safe to use in children and young people with ALL.

Drugs

December 2017

Esketamine for Treatment-resistant Depression

Currently there are no approved treatments for patients with depression who are at an imminent risk for suicide. Esketamine is currently in development as a spray through the nose (intranasal) for the treatment of treatment-resistant depression in adults.

Drugs

Drugs

December 2017

Tocilizumab (RoActemra) for Adults with Systemic Sclerosis – Second Line

There is currently no cure for systemic sclerosis and treatment options focus on the management of symptoms. Tocilizumab is intended for the treatment of systemic sclerosis in adults. It is currently in development and early research indicates that it is able to target the key mechanisms thought to be responsible for the disease. If licensed, …

Drugs

December 2017

Lenadogene Nolparvovec (GS-010) for Vision Loss from Leber’s Hereditary Optic Neuropathy Due to Mutation of the ND4 Gene

There are currently very few treatment options for LHON. Most treatment methods are used to support the patient rather than cure them. Lenadogene nolparvovec is a new gene-targeted treatment intended for vision loss caused by LHON due to an alteration in a specific gene. As a genetic medicine, lenadogene nolparvovec could be a promising option …

Drugs

December 2017

Neridronic Acid (Nerixia) for Complex Regional Pain Syndrome

Currently there are no approved treatments for CRPS. Neridronic acid administered by injection is currently being developed to treat CRPS and early results indicate that it has the possibility to control the condition. If approved neridronic acid will be a potential new treatment for CRPS.

Drugs

December 2017

Upadacitinib for Adults with Moderate to Severe Active Rheumatoid Arthritis After Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs) or Biologic DMARDs Failure

There is currently no cure for rheumatoid arthritis and treatment aims to improve quality of life and to prevent or reduce joint damage. The most common treatment options are steroids to reduce inflammation, medications to reduce pain and swelling, and medications that slow the progression of joint damage from RA. Upadacitinib is currently being developed …

Get Alerts